lol646 customer service
Easyjet is set to report more than half a billion in profit in its full-year results next Wednesday as it continues to cash in on strong demand for travel in the post-Covid era. The orange-liveried carrier is expected to haul in £595m in pre-tax profit, up from £455m the year prior. Analysts are forecasting capacity growth of eight per cent to 100m in the 12 months to September, and five per cent on a compound basis going forward. Dividends are expected to come in at 12p a share, with a further increase to 14.8p in 2025. The results come in a year in which the share price of Europe’s three largest budget airlines, Ryanair, Easyjet and Wizz Air, has largely underwhelmed. Shares in Easyjet are broadly level, up two per cent in 2024, despite record flight demand across the continent. Ryanair sparked a sell-off in London-listed airline stocks over summer after it reported a drop in profit and warned over falling ticket fares. Delivery delays at the world’s two largest planemakers, Airbus and Boeing, have also left airlines struggling to hit capacity targets. However, the FTSE 350 firm has shown resistance to the external issues, in part due to the performance of its package holiday division, Easyjet holidays. That segment is expected to rake in more than £180m over the period, up from £122m, as it closes in on a medium-term target of £250m. “Easyjet’s last set of results landed well with markets , who had become nervous after rival Ryanair issued a weak performance over the same period,” Aarin Chiekrie, an equity analyst at Hargreaves Lansdown, said. “But Easyjet bucked the trend by selling a higher percentage of its available seats for the fourth quarter, despite increasing its capacity by 7 per cent. This was enough to reassure investors that the group remains on the right flight path to deliver another record-breaking summer,” he said. “It’s unlikely to be the start of a fully-fledged price war between the low-cost carriers, but it’s something the market will be keeping a keen eye on. Recent industry data shows that air travel demand continues to soar higher, and investors are eager to hear what easyJet sees on the horizon in next week’s results,” Chiekrie added. Wednesday’s results will be the last of Easyjet’s long-serving chief executive Johan Lundgren, who is due to step down in January. He will be replaced by the firm’s finance chief, Kenton Jarvis.
Rehmat-e-Alam Hospital awaits approval after 5-year halt‘Executions’: Frightening next steps in SyriaAccording to Bersamin, the scheduled signing of the proposed P6.352-trillion 2025 national budget on Friday, Dec. 20, is postponed to give way to a review led by Marcos himself. President Marcos is set to veto certain provisions of the 2025 General Appropriations Act (GAA) in the interest of public welfare, Malacañang announced early Wednesday morning, Dec. 18. This development came following budget cuts in the Department of Education (DepEd) and the Philippine Health Insurance Corporation (PhilHealth). "We can now confirm that certain items and provisions of the national budget bill will be vetoed in the interest of public welfare, to conform with the fiscal program, and in compliance with laws," Executive Secretary Lucas Bersamin said in a statement. According to Bersamin, the scheduled signing of the proposed P6.352-trillion 2025 national budget on Friday, Dec. 20, is postponed to give way to a review led by Marcos himself. "The scheduled signing of the General Appropriations Act on December 20 will not push through to allow more time for a rigorous and exhaustive review of a measure that will determine the course of the nation for the next year," he said. "The ongoing assessment is being led by the President himself, in consultation with the heads of major departments," he added, noting that there is no new date for the signing yet. Early this week, President Marcos defended the significant increase in the proposed budget of the Department of Public Works and Highways (DPWH), saying the government must spend for the safety of the people. The proposed DPWH budget has bloated to P1.113 trillion from the initial P900 billion after the bicameral conference committee meeting. "But public works is still going to be one of the top recipients of budget because marami na tayong ginagawa (we are doing many things)," Marcos said. "We have big projects that we have to put in place. Infrastructure is important. And don't forget flood control became such a big, big part of the work of the DPWH," he added. On the other hand, the President said they are working to restore the P10-billion cut in the proposed budget for the DepEd. He said the budget cut contradicted his administration's policy direction regarding Science, Technology, Engineering, and Mathematics (STEM). "I think we'll still be able to do it, to be able to do something. Maybe this is the first thing, hindi pa buo ang sagot ko pero sasabihin ko na sa inyo, tinatrabaho namin 'yan (my answer is not complete yet but I will say now that we are working on it)," Marcos said. "You know, P12-billion request, the original request of the P12 billion to be reduced down to two. P12 billion is only sufficient to maintain what we're already doing when in fact we have to do more. So yun na nga, we have to figure that out. But we are," he added. Despite this, President Marcos said he will strive to sign the 2025 GAA before Christmas.
adtechnacity Named to Deloitte Technology Fast 500TM After 1,829% Growth and $100M MilestoneNone
BBC host Lauren Laverne given the 'all clear' from cancer
Remember National Victory Day to initiate future StateJimmy Carter, Longest-Living U.S. President, Dies at 100CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that updated clinical data for RLY-2608 600mg BID + fulvestrant in patients with PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast cancer will be presented at the upcoming San Antonio Breast Cancer Symposium, taking place December 10-13, 2024. Details of the RLY-2608 + fulvestrant poster presentation are as follows: Abstract Title: PS7-01: Efficacy of RLY-2608, a mutant-selective PI3Kα inhibitor in patients with PIK3CA-mutant HR+HER2- advanced breast cancer: ReDiscover trial Abstract Number: SESS-2211 Session: Concurrent Poster Spotlight Session 7: Targeting the ER and PI3K pathway: Novel drugs and combinations Date/Time: Wednesday, December 11, 8:00-9:30 a.m. ET (7:00-8:30 a.m. CT) Conference Call Information Relay Therapeutics will host a conference call to discuss these data on Wednesday, December 11, 2024 at 7:00 a.m. ET (6:00 a.m. CT). Registration and dial-in for the conference call and webcast may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations . An archived replay of the webcast will be available following the event. The poster will be available at the start of the session on the company’s website at https://relaytx.com/publications/ . About RLY-2608 RLY-2608 is the lead program in Relay Therapeutics’ efforts to discover and develop mutant selective inhibitors of PI3Kα, the most frequently mutated kinase in all cancers, with oncogenic mutations detected in about 14% of patients with solid tumors. RLY-2608 has the potential, if approved, to address more than 300,000 patients per year in the United States, one of the largest patient populations for a precision oncology medicine. Traditionally, the development of PI3Kα inhibitors has focused on the active, or orthosteric, site. The therapeutic index of orthosteric inhibitors is limited by the lack of clinically meaningful selectivity for mutant versus wild-type (WT) PI3Kα and off-isoform activity. Toxicity related to inhibition of WT PI3Kα and other PI3K isoforms results in sub-optimal inhibition of mutant PI3Kα with reductions in dose intensity and frequent discontinuation. The Dynamo® platform enabled the discovery of RLY-2608, the first known allosteric, pan-mutant, and isoform-selective PI3Kα inhibitor, designed to overcome these limitations. Relay Therapeutics solved the full-length cryo-EM structure of PI3Kα, performed computational long time-scale molecular dynamic simulations to elucidate conformational differences between WT and mutant PI3Kα, and leveraged these insights to support the design of RLY-2608. RLY-2608 is currently being evaluated in a first-in-human trial designed to treat patients with advanced solid tumors with a PIK3CA (PI3Kα) mutation. For more information on RLY-2608, please visit here . About Relay Therapeutics Relay Therapeutics is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter . Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Relay Therapeutics’ strategy, business plans and focus; the progress and timing of the clinical development of the programs across Relay Therapeutics’ portfolio; the expected therapeutic benefits and potential efficacy and tolerability of RLY-2608, both as a monotherapy and in combination with other agents, and its other programs, including lirafugratinib as well as the clinical data for RLY-2608; the interactions with regulatory authorities and any related approvals; the potential market opportunity for RLY-2608; the cash runway projection and the expectations regarding Relay Therapeutics’ use of capital, expenses and potential cost savings. The words “may,” “might,” “will,” “could,” “would,” “should,” “plan,” “anticipate,” “intend,” “believe,” “expect,” “estimate,” “seek,” “predict,” “future,” “project,” “potential,” “continue,” “target” and similar words or expressions, or the negative thereof, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: the impact of global economic uncertainty, geopolitical instability and conflicts, or public health epidemics or outbreaks of an infectious disease on countries or regions in which Relay Therapeutics has operations or does business, as well as on the timing and anticipated results of its clinical trials, strategy, future operations and profitability; the delay or pause of any current or planned clinical trials or the development of Relay Therapeutics’ drug candidates; the risk that the preliminary or interim results of its preclinical or clinical trials may not be predictive of future or final results in connection with future clinical trials of its product candidates and that interim and early clinical data may change as more patient data become available and are subject to audit and verification procedures; Relay Therapeutics’ ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of its planned interactions with regulatory authorities; and obtaining, maintaining and protecting its intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Relay Therapeutics’ most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Relay Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. Relay Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Contact: Megan Goulart 617-322-0814 mgoulart@relaytx.com Media: Dan Budwick 1AB 973-271-6085 dan@1abmedia.com
Mr Forro was one of two employees to have put food out and fed the fox and the other security guard was Irish. Fox. Photo: Stock A security guard who was sanctioned by his employer for feeding a fox while on duty at a pharma site has been awarded €6,000 in a race discrimination case. At the Labour Court, deputy chairwoman, Louise O’Donnell found that Apleona Ireland Ltd discriminated against Hungarian national, Istvan Forro on the grounds of race when suspending him for 14 weeks with pay over the ‘feeding fox’ incident in January 2021. Ms O’Donnell stated that Mr Forro was subjected to an investigation and disciplinary hearing and received a sanction of a verbal warning which he successfully appealed internally. Mr Forro was one of two employees to have put food out and fed the fox and the other security guard was Irish. Ms O’Donnell said that the comparator in the case, the Irish employee, Mr A was not spoken to by his employer over the ‘fox’ incident and was not penalised in any way for the same actions. Ms O’Donnell stated that the court is satisfied that these facts are sufficient to raise a presumption of discrimination and that Apleona Ireland failed to rebut the presumption of unlawful discrimination. The Labour Court ruling overturns an earlier decision by the Workplace Relations Commission (WRC) which found that Mr Forro had not been discriminated against. The most recent accounts for Apleona Ireland Ltd show that it recorded pre-tax profits of €4.34m in 2022 as revenues increased by 19pc to €94.4m. Under cross examination at the Labour Court hearing held in Waterford, Mr Forro confirmed that he liked the fox and that he had admitted to feeding the fox. Mr Forro stated that he was the only Hungarian member of staff, and the only person suspended and investigated over feeding the fox. Mr Forro confirmed that he was never told to stop feeding the fox until January 2021. He confirmed that he had worked on the same site for a number of years prior to Apleona taking over and he stated that a group of workers had fed the fox, and he felt that the client company were aware of it. Mr Forro said that January 2021 was the first time it was raised with him that there was a problem with feeding the fox. He said that he stopped feeding the fox and made a point of telling other staff that they were not to feed the fox. Mr Forro said that as he was about to return to work in late January 2021 after a bout of Covid-19, he received a phone call from a senior work colleague to say he was suspended with pay and not to go on site or make contact with anyone on site. He asked why he was being suspended and he was told “it was something about a fox.” Mr Forro received a letter which stated that was suspended on full pay to allow an investigation into an alleged failure to follow management instruction on more than one occasion; an alleged failure to obey the sites Pest Control Standard Operating Procedures; a breach of trust with Management and putting the relationship with the client in jeopardy. The letter went on to say that “at this point that these allegations would be considered gross misconduct”. In May 2021, Mr Forro received a letter confirming a verbal warning when he was told that “based on the balance of probabilities I have come to the conclusion that you breached policies and attempted to deceive the company which amounts to serious/gross misconduct. This conduct is in excusable”. Mr Forro stated that the only difference between himself and his work colleague was that he was Hungarian and his colleague was Irish. He said that they were both accused of leaving food out and feeding the fox, but he was the only one suspended and put through an investigation procedure. Mr Forro contended that that the photo of food produced at the meeting was not the type of food that they would leave for the fox. An associate director with Apleona, Ms Krakowiak told the Labour Court that in January 2021 she received an email from the client firm about food being dumped on the site and was asked by the client to investigate. Ms Krakowiak reviewed the CCTV footage and saw Mr Forro and Mr A feeding the fox. Counsel for Mr Forro, Mr Joseph Bradley BL (instructed by Sean Ormonde Solicitors) put it to Ms Krakowiak that Apleona needed a scapegoat for the client, and they chose the Hungarian rather than the Irish national. Mr Bradley stated that the issue should have come to an end on April 9, 2021, when Mr Forro confirmed he had not received training about not feeding the fox. Ms Krakowiak submitted that the reason for the different treatment was that Mr Forro had received training in pest control and Mr A had not. However, in the court’s finding, Ms O’Donnell stated that the notes of meetings held with Mr Forro in April 2021 clearly show that he stated on each occasion that he had not received training and this position was upheld by the person who heard the appeal of his disciplinary sanction.Bushra Bibi granted interim bail in four Nov 26 protest casesShohei Ohtani's eventual return to the mound isn't going to come at the start of the 2025 season. Los Angeles Dodgers manager Dave Roberts told reporters on Monday it was "very unlikely" that Ohtani would be able to pitch by then, though added he expects him to be ready to go as a hitter. The superstar slugger had arthroscopic surgery for a torn labrum in his left shoulder in November. This article will be updated soon to provide more information and analysis. For more from Bleacher Report on this topic and from around the sports world, check out our B/R app , homepage and social feeds—including Twitter , Instagram , Facebook and TikTok .
Super Micro Computer, Snowflake And MicroStrategy Are Among Top 10 Large-Cap Gainers Last Week (Nov 18-Nov 22): Are The Others In Your Portfolio? - BenzingaTruck Charging: Start Small, Scale Smart
- Previous: lol646 com download
- Next: lol646 download android latest version apkpure